Our concept of cancer latency, the interval from when a cancer starts until it is diagnosed, has changed dramatically.  A prior widely-used definition was the interval between an exposure to a cancer-causing substance and cancer diagnosis.  

The most challenging part of NGS-based IGHV analysis in CLL concerns the interpretation of the findings rather than the analysis per se. ERIC and EuroClonality-NGS are working hard on addressing open issues and on standardization. See Davi et al., Leukemia 2020, doi: 10.1038/s41375-020-0923-9.

Binod Dhakal, Anita D'Souza, Saurabh Chhabra, Parameswaran Hari, Medical College of Wisconsin Milwaukee, WI, USA